Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.